Figure 4.

ISG15 promotes tumor progression and Gemcitabine resistance in vivo. A, Tumor size derived from ISG15-depleted or control PANC-1 cells with or without Gemcitabine treatment were measured in Balb/c nude mice. B-C, Tumor size (B) and weight (C) were measured after tumor excision at day 42. D, IHC staining of ISG15 and Ki67 and the results of TUNEL assays are shown (scale bar =50 μm). E-F, Statistic results of tumor weight (E) and the percentage of TUNEL-positive (apoptotic) cells (F) in PANC-1 derived tumors with different treatments. (* p<0.05; ** p<0.01; *** p<0.001).